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ABSTRACT
Three patients with propionic acidemia were studied. The first 
patient was diagnosed at the age of 9 mo, 3 mo after he 
developed hypotonia and choreoathetoid movements after an 
upper respiratory tract infection. The second patient was diag­
nosed at the age of 1.5 mo when she became comatose after 
nasogastric tube feeding because of failure to thrive. The third 
patient was diagnosed at the age of 5 d when she presented with 
feeding difficulties, hypotonia, and respiratory insufficiency. 
Magnetic resonance imaging (MRI) of the brain in all patients 
revealed delayed myelination and some cerebral atrophy. In the 
patient with choreoathetosis, MRI showed bilateral abnormalities 
in the signal intensity of the putamen and caudate nuclei. MRI of 
the other two patients showed normal basal ganglia. Proton 
magnetic resonance spectroscopy (!H MRS) from a voxel lo­
cated in the basal ganglia revealed a decrease in TV-acetylaspar- 
tate and myoinositol peaks and an elevation of glutamine/ 
glutamate. The presence of spectroscopic abnormalities in a 
stable metabolic condition, in particular the rise in glutamine/
glutamate, indicates that the metabolic balance on cerebral pa­
renchymal level is less optimal than estimated from biochemical 
analysis of urine, plasma, or cerebrospinal fluid. (Pediatr Res 40: 
404-409, 1996)
Abbreviations 
Cho, choline-containing compounds 
Cr, creatine and phosphocreatine 
CSF, cerebrospinal fluid 
GIx, glutamine and glutamate 
ml, myo-inositol
MRI, magnetic resonance imaging
MRS, magnetic resonance spectroscopy
NAA, N-acetylaspartate
ppm, parts per million
GABA, y-aminobutyric acid
STEAM, stimulated-echo acquisition mode
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Propionic acidemia is a genetic disorder of amino acid 
metabolism caused by a deficiency of propionyl-CoA carbox­
ylase (1-3). The first clinical presentation may be manifest at 
any age from the neonatal period on, The spectrum of possible 
clinical symptoms is wide. Many patients exhibit poor feeding, 
vomiting, and lethargy leading to coma if onset of treatment is 
delayed. Metabolic derangement may be precipitated by infec­
tion or excessive protein intake (4). Ketoacidosis and hyper­
ammonemia are prominent laboratory findings, in particular 
during episodes of metabolic decompensation. The reported 
neurologic symptomatology is diverse. Frequently observed 
neurologic signs are axial hypotonia, extrapyramidal manifes­
tations, and seizures (see Table 1). Surtees et a l  (5) recently 
reported the neurologic outcome of 20 patients with propionic 
acidemia. Extrapyramidal movements were a prominent find­
ing in both the early-on set group and the late-onset group (Table 
1 ). In the late-onset group, bilateral basal ganglia hypodensities 
were observed on cranial computer tomography when performed 
shortly after the onset of the movement abnormalities. These 
lucencies resolved completely in most patients over a 1-3-mo 
period after the onset of dietary treatment (5). The pathophysiol­
ogy of these basal ganglia abnormalities is unknown.
We report proton (*H) MRS studies of the basal ganglia in 
three patients with propionic acidemia (one with an early onset, 
two with the late-onset form). The aim of the study was to 
investigate whether MRS may contribute to the insight of 
the underlying mechanisms accounting for the basal ganglia 
damage in propionic acidemia and whether JH MRS may 
contribute in the monitoring of treatment.
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METHODS
Three children with propionic acidemia were studied. The 
diagnosis was made on the basis of clinical presentation,
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urinary metabolite excretion pattern, and in vitro enzyme 
assays. Propionyl-CoA carboxylase activity in cultured skin 
fibroblasts ranged from 0.2 to 1 nmol/h/mg protein (normal 
15-75). The clinical symptoms are summarized in Table 1. 
Patient 1 presented at the age of 6 mo with hypotonia and 
choreoathetoid movements and was diagnosed at 9 mo of age. 
Patient 2 came to attention at the age of 1.5 mo when she 
became comatose after nasogastric tube feeding because of 
failure to thrive. Patient 3 was diagnosed at the age of 5 d when 
she presented with feeding difficulties, hypotonia, and respira­
tory insufficiency. Patients 2 and 3 required hemodialysis or 
peritoneal dialysis. Once the diagnosis was made, all of the 
patients were treated with a low protein diet and were given a 
trial of biotin, which was discontinued when they were shown 
to be unresponsive. Patient 1 was followed up to his present 
age of 36 mo and is still severely retarded and choreoathetotic. 
Patient 2 presented a normal development at the age of 3 mo, 
Patient 3 had initially repeated episodes of metabolic decom­
pensation, but has remained stable now for 1 y. At 32 mo of 
age she was still retarded, but she had improved considerably 
during the last year. At no time choreoathetosis was noted. 
MRI and MRS of the brain were performed in all three 
patients during stable clinical and biochemical conditions.
Organic acids in plasma, urine, and CSF were quantitated by 
gas chromatography (6). A standard amino acid analyzer was 
used to determine the amino acids in plasma, urine, and CSF. 
CSF concentrations of free and total GABA were determined 
by using a stable isotope dilution gas chromatography/mass 
spectrometry assay (7).
MRI and MRS were performed on a 1.5 Tesla MR instru­
ment. Sagittal T r weighted images and transverse T r  and 
T 2-weigh ted images were made. The standard imaging head- 
coil was used for MRS. A 2 X 2 X 2-cm voxel was chosen 
in the area of the caudate nucleus, putamen, globus pallidus, 
and thalamus on the left side, containing a mixture of white 
and, in particular, central gray matter. The STEAM sequence 
was used with a repetition time of 2500 ms, an echo time of 20 
ms, and 128 acquisitions [see Frahm et a l  (8) for all technical 
details]. The averaged measurements were zero-filled to 2048 
data points, exponentially filtered to give 1 Hz line-broadening 
before fast-Fourier transformation. The spectra were quantified 
by peak area measurements using system software (Siemens 
SP63). The following peaks were quantified: NAA (2.02 ppm), 
GIx (2 .1-2.5 ppm), “creatine” representing creatine and phos- 
phocreatine (Cr, 3.02 ppm), “choline” representing choline- 
containing compounds (Cho, 3.20 ppm), and ml (3.56 ppm). 
To determine a baseline, four fixed areas were used: left foot of 
the NAA peak (2.02 ppm), area between the Cr peak (3.02 
ppm) and the NAA peak at 2.70 ppm, left foot of the ml peak 
(3.56 ppm), and the area at the right of the Cr peak at 3.93 ppm. 
The peaks of spectra were normalized to the Cr peak (3.02 
ppm). Creatine age- and area-dependent values were used as 
known from the literature (9, 10). An exception was made for 
the region between 2.1 and 2.5 ppm, containing multiple 
overlapping peaks representing glutamine, glutamate, and 
some GABA (together Glx). The ratio of the integral of this 
area and the creatine peak was used as a rough indication of the 
concentration of the contributing metabolites. The control
Table 1. Clinical symptoms and CT/MRI findings in propionic acidemia patients
Author (reference) Sex Age at onset Clinical presentation CT/MRI findings (age)
Barnes and Enzmann, 
1981 (27)
M 7 d Seizures, lethargy, hypertonia Diffuse decreased density periventricular white matter 
(2  wk), cerebral atrophy (8 mo)
Gebarski et al., 1983 
(28)
F 2 mo Spastic quadriparesis Diffuse cerebral atrophy (3.5 y)
F 17 y Mental retardation Lucency in posterior limb of right internal capsule
(17 y)
Kurczynski et al., 
1989 (29)
M 10 d Generalized hypotonia, no functional 
motor disability
Increased ventricular size (6 y)
Sethi eta l, , 1989
(13)
M 28 y Intellectual deterioration, confused, 
and involuntary hand and facial 
move men Us
Slight asymmetry of frontal horns, nucleus caudatus 
normal (31 y)
Surtees et al., 1992
(5)
3 d Dystonia, hypotonia at 18 mo Cerebral atrophy (18 mo)
ï d No movement disorder Cerebral atrophy
--- 2 d Chorea at age 2 mo Cerebral atrophy (2 mo)
2  y Chorea with bulbar involvement, 
dystonia, pyramidal signs
Low density in lentiform nuclei (2 y)
6 mo Chorea with bulbar involvement, 
pyramidal signs
Low density caudate and lentiform nuclei, normal 
thalami; low densities resolving over 2 mo (6 mo)
--- 6 wk No movement disorder Low density lentiform nuclei, part of thalami and 
white matter; low densities resolved over 3 mo
Haas et al., 1995 (15) F 2 d Seizures, apnoea. Encephalopathy with 
lethargy and confusion at 8 y
Transient bilateral signal caudate nucleus, globus 
pallidus, and putamen (8 y). Acute basal ganglia 
infarction after pancreatitis (9 y)
Patient 1 M 6 mo Hypotonia, choreoathetosis Low densities putamen and nucleus caudatus (10 mo)
Patient 2 F 1.5 mo Comatose upon nasogastric tube 
feeding, axial hypotonia and distal 
hypertonia
No abnormalities basal ganglia (2 mo)
Patient 3 F 5 d Hypotonia, diminished consciousness, 
psychomotor retardation
No abnormalities basal ganglia (1.5 y)
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group for the MRS investigations consisted of eight healthy 
children varying in age from 3 to 48 mo.
RESULTS
Results of biochemical studies are summarized in Table 2. In 
the period of the lH MRS all patients had normal plasma 
ammonia values. The urinary 3-OH-propionic acid concentra­
tion was elevated in all patients. The free and total GAB A in 
CSF was normal, whereas CSF glycine and alanine concentra­
tions were increased in all patients.
Initial MRI of all patients showed a mildly enlarged ven­
tricular system and subarachnoid spaces. The MRI of patient 1 
at 10 mo of age (Fig. 1) showed an abnormally high signal 
intensity on T2-weighted images, abnormally low on T r  
weighted images in the caput and corpus of the caudate nucleus 
and in the putamen. Globus pallidus and thalamus were nor­
mal. Myelination of the cerebral hemispheres was delayed and 
irregular with patchy areas of high signal intensity on T2- 
weighted images and low signal intensity on T r-weighted 
images. At the age of 24 and 36 mo the repeat MRIs showed 
progress in myelination and diminishing cerebral atrophy, but 
the basal ganglia abnormalities remained unchanged.
MRI of patient 2, made at the age of 2 mo, showed, apart 
from some cerebral atrophy, no other abnormalities. The im­
ages showed the beginning of myelination and normal basal 
ganglia.
At 20 mo of age the MRI of patient 3 showed mildly delayed 
myelination, which was not yet completed in the temporal 
lobes and in the directly subcortical areas. Some mild and 
patchy increases in signal intensity were seen in the frontal and 
occipital periventricular white matter on T2-weighted images. 
The basal ganglia were normal. Repeat MRI at the age of 32 
mo showed considerable improvement of myelination and 
diminished cerebral atrophy.
The spectroscopic data from the area of the basal ganglia 
of the patients were compared with those of the eight
Figure 1. MRI of the brain of patient 1 at the age of 10 mo. The T2-weighted 
MR images show enlarged subarachnoid spaces and ventricular system, lesions
in the putamen and caudate nucleus, and delayed myelination.
i.
healthy controls. The data are summarized in Table 3 (see 
also Fig. 2 ). In all patients the level of NAA was decreased. 
The Cho level in patients 1 and 3 did not differ from the 
level in controls, but was elevated in patient 2. In patients 1,
T able  2. L a b o ra to ry  fin d in g s  o f  p a tie n ts  w ith  p ro p io n ic  a c id em ia  u nder trea tm ent, p e r fo rm e d  in  the  sam e p erio d  as !H  M R S  investiga tion
Laboratory findings
Patient
Control 
(mean ±  SD; min-max)
1 2  
2 mo
3
10 mo 24 mo 36 mo 20  mo 32 mo
Plasma (jxmol/L)
Ammonia 53 45 53 42 52 77 35-85
Glutamine 536 552 600 625 596 567 596 ± 66
Glutamate 68 69 68 118 36 66 14-78
3-OH-Propionic acid 40 35 68 99 0-4
Urine (/xmol/mmol creatinine)
3-OH-Propionic acid 33 86 102 21 256 0 -8
CSF (/imol/L)
Free GAB A 0.033 0.02 0.027 0.017-0.142*
Total GAB A 5.4 5.2 13.3 4.1-13.4*
Glutamine 347 390 499 365 343 427 509 ± 44
Glutamate 5 7 1 18 15 7 ± 5
Glycine 27 27 29 32 18 12 6.6 ± 2
Alanine 47 51 54 76 53 57 23 ± 9
3-OH-Propionic acid 19 7 150 34 57 53 0-91
Lactate 2600 2900 2677 2949 2841 2508 450-2100t
* From Kok et al. (7). 
t  From Hoffmann et al. (30).
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Table 3. 1H MRS findings of basal ganglia in patients with
propionic acidemia and normal controls
Patient Age (mo)
NAA*
(2.02 ppm)
Glx/Cr 
(Glx 2.1-2.4 
ppm)
Cho* 
(3.2 ppm)
ml* 
(3.56 ppm)
1 1 0 6,9 1.4 1.7 7.3
1 24 8,3 1 . 6 1 . 6 6 . 2
1 36 8 . 8 1.5 1 . 6 6 . 2
2 2 5.7 1.5 2.7 5.8
3 2 0 7.3 1 . 2 1.5 7.0
3 32 8.5 1.3 1.5 6 . 2
Controls
1 3 8.5 1 . 2 2 . 1 8.5
2 3 8 . 2 1 . 2 2 . 1 8 . 6
3 3 8.4 1 . 2 2 . 2 8,5
4 3 8.3 1 . 1 2 . 1 8.9
5 6 9.4 1 . 2 1 . 8 7.9
6 15 10.5 1 . 2 1 . 6 7.7
7 36 10.4 1 . 2 1.5 7,3
8 48 10.7 1 . 2 1.5 7.4
* Millimoles/kg of brain tissue.
Choi
45 35 aö 2Ü 2S Ï5  15 0 5
Chemical shift / ppm
Chemical shift / ppm
Figure 2. Short echo time STEAM spectrum obtained from the area of the 
basal ganglia on the left side in patient 2 (upper spectrum), compared with a 
normal spectrum of a control child of the same age (lower spectrum). Note the 
decrease in NAA (2,02 ppm), increase in Glx (2.1-2.4 ppm), rise in Cho (3.2 
ppm), and decrease in ml (3.56 ppm) relative to Cr (3.02 ppm) in patient 2 
compared with the control.
2, and to a lesser extent in patient 3, elevated signals were 
seen in the range of 2.1-2.5 ppm, indicating a rise in Glx. In 
all patients ml was decreased.
DISCUSSION
Propionic acidemia is caused by a defect in the carboxyla­
tion of propionyl-CoA to methylmalonyl-CoA. Biochemically 
this disorder is characterized by moderate to severe ketoacido­
sis, hyperglycinemia, and hyperammonemia. The acidosis is 
the result of accumulation of various normal and abnormal 
organic acids, in particular propionate, 3-hydroxybutyrate, 
methylcitrate, and 3-hydroxypropionate. Propionate is derived 
from hydrolysis of propionyl-CoA and is detectable in all body 
fluids. The hyperammonemia during acute episodes is thought 
to be caused by the inhibitory effects of propionyl-CoA on 
AT-acetylglutamate synthetase, the first enzyme involved in 
ureagenesis ( 1 1 ).
Although the metabolic routes of the production of abnormal 
acids in propionic acidemia are known ( 12 ) and the effects of 
these organic acids on different organ systems have been 
studied, the explanation for the heterogeneous clinical presen­
tation is unknown (13). The differentiation between the early- 
onset and late-onset group can neither be made on the basis of 
different genetic mutations (14), nor on the basis of different 
levels of residual activity of propionyl-CoA carboxylase (13). 
In general, episodes of clinical deterioration are accompanied 
by metabolic decompensation, but clinical deterioration and 
necrosis of the basal ganglia have been described despite 
documented excellent metabolic control at the time of onset of 
the cerebral dysfunction (15).
Our three patients had different clinical presentations. Pa­
tient 1 presented with choreoathetosis at the age of 6 mo. 
Despite adequate treatment the choreoathetosis persisted, prob­
ably because of irreversible damage of the basal nuclei. The 
delay in treatment may be important in this respect. MRI of the 
brain at the age of 10, 24, and 36 mo showed symmetrical 
lesions in the putamen and caudate nucleus, in addition to a 
delay in myelination and some cerebral atrophy. Patients 2 and 
3 presented clinical symptoms at 1.5 mo and 5 d, respectively. 
They had no choreoathetosis, nor abnormalities of the basal 
nuclei.
Bilateral lesions of the basal nuclei have been often noted in 
propionic acidemia, in particular in the late-onset variant (Ta­
ble 1). The pathophysiologic mechanisms underlying these 
lesions, however, are still unknown.
The MRS findings from the basal ganglia in our patients 
were essentially identical showing decreased NAA, increased 
Glx, and decreased ml peaks in comparison with the values 
found in healthy controls. These changes were reproducible in 
follow-up. The decreased level of NAA is commonly ascribed 
to neuronal dysfunction, damage, or loss (16), It is possible that 
the decrease in NAA can be partially ascribed to delayed 
neuronal maturation.
At the lower magnetic field strengths used in clinical studies, 
the separation of glutamine from glutamate is not possible. The 
elevation of Glx may represent an increase in glutamine (17- 
20). Elevated glutamine peaks in MRS of the brain have been 
described most often in hyperammonemia (17-20). Hyperam­
monemia leads to enhanced production of glutamine and glu­
tamate from 2~oxoglutarate. Glutamate is a major excitatory 
neurotransmitter, whereas GAB A, formed by decarboxylation
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from glutamate, is the most important inhibitory neurotrans­
mitter. In the presynaptic neuron, glutamine is converted to 
glutamate and ammonia by glutaminase. Glutamate can either 
be converted to GAB A by glutamic acid decarboxylase or be 
released in the synaptic cleft. After release by the presynaptic 
neuron, glutamate is taken up by the astrocyte where it is 
converted into glutamine by glutamine synthetase and then 
transported back to the presynaptic neuron. This cycle operates 
mainly between the pi'esynaptic neuron, the neuronal cleft, and 
the astrocyte. Hyperammonemia has a great impact on this 
cycle by stimulating glutamine synthesis via glutamine syn­
thetase, by possible inhibition of glutaminase, and by inhibition 
of glutamate re-uptake by the astrocyte. High plasma ammonia 
levels would lead to an accumulation of glutamine in the brain, 
mainly in astrocytes. An imbalance between excitatory and 
inhibitory neurotransmitters may contribute to the cerebral 
dysfunction. Accumulation of intracellular glutamine is re­
flected in elevated Glx in MRS (17-20). However, at the 
time of !H MRS in our three patients, the plasma ammonia 
concentration and the plasma and CSF concentrations of glu­
tamine and glutamate were normal or just above normal (see 
Table 2). This indicates that blood and CSF concentrations 
may differ from tissue concentrations. Differences between 
blood, CSF, and brain parenchyma metabolite concentrations 
have been reported before in metabolic disorders, in particular 
with respect to lactate in mitochondrial disorders (2 1 , 22). 
MRS may reveal considerable elevation of lactate in brain 
tissue, whereas lactate in CSF and blood is normal or only 
slightly elevated (2 1 ). On the other hand, MRS may not show 
any evidence of elevated lactate, whereas CSF lactate is high 
(22). Assessment of brain tissue metabolite concentrations by 
MRS is an additional method for monitoring metabolic stabil­
ity at tissue level to the biochemical analysis of urine, plasma, 
and CSF.
Glutamate is a major excitatory neurotransmitter in the CNS 
and is well known for its excitotoxic effects in many forms of 
brain damage, particularly in hypoxia-ischemia. Elevated Glx 
reflecting elevated glutamate has been found in cases of acute 
cerebral hypoxia-ischemia (23-25). The elevated Glx that we 
found in our patients could be a sign of active excitotoxic 
damage of the basal nuclei. Considering the clinical and met­
abolic stability of the patients at the time of MRS, this hypoth­
esis is less attractive.
Another possible explanation for basal nuclei dysfunction in 
propionic acidemia could be alterations in mitochondrial en­
ergy metabolism causing accumulation of toxic metabolites 
(15). The presence of elevated cerebral lactate levels is an 
argument in favor of this hypothesis. However, although we 
found slightly increased lactate values in CSF, we found no 
spectroscopic evidence of increased lactate within the brain in 
our patients.
It has been suggested that one or more of the metabolites 
accumulating in propionic acidemia is neurotoxic (15). Our 
data show that 3-OH-propionate is the only metabolite of the 
propionate derivatives detectable in large quantity in CSF. 
Unfortunately this metabolite could not be detected by MRS 
methods.
Reduced cerebral ml as found in our patients has also been 
observed in patients with hyperammonemia and elevated Glx 
levels. Glycine co-resonates with ml at 3.56 ppm (26). CSF 
glycine was elevated in all patients. It cannot be excluded that 
ml was actually lower than now estimated, because the de­
crease in peak area was partly compensated by the increase in 
glycine. However, it is not probable that there was a major 
contribution of glycine in our patients. In all patients additional
spectra were acquired with a longer echo time (135 ms). These
•i
did not show the presence of a resonance at 3.56 ppm, which 
would have been expected in the case of elevation of glycine. 
The significance of the ml reduction is not understood. It is 
generally believed that ml plays a role as a precursor of the 
inositol polyphosphate family of intracellular messengers. It 
may play an important role in the detoxification reactions of the 
brain (17, 18), and it has been suggested that low ml may be 
the result of enhanced use of detoxification processes. Another 
function of ml may be that of osmoregulator (17, 18). It is 
possible that the decrease in ml is compensatory for the 
increase in Glx to maintain osmotic balance in the brain.
The observation of spectroscopic abnormalities in metabol- 
ically stable patients is important. Serious, even fatal, neuro­
logic deterioration with basal ganglia necrosis may occur in 
patients who are in a stable metabolic condition as estimated by 
conventional biochemical analyses (15). The current study 
shows that biochemical changes at tissue level as seen by 
MRI/MRS differ from the results obtained by biochemical 
analysis of body fluids. MRS of the brain in vivo would provide 
a valuable, nonin vas ive tool in monitoring patients with pro­
pionic acidemia and other inborn errors of organic acid me­
tabolism. In this respect MRI and MRS would have comple­
mentary values, MRI reflecting both temporary and permanent 
cerebral structural damage, and MRS reflecting actual intracel­
lular biochemical changes at tissue level.
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